Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CytomX Therapeutics Q2 2024 GAAP EPS $(0.08) Beats $(0.10) Estimate, Sales $25.115M Beat $19.995M Estimate

Author: Benzinga Newsdesk | August 08, 2024 05:39pm
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.10) by 20 percent. The company reported quarterly sales of $25.115 million which beat the analyst consensus estimate of $19.995 million by 25.61 percent. This is a 1.58 percent increase over sales of $24.724 million the same period last year.

Posted In: CTMX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist